CMPS — COMPASS Pathways Plc - American

Is CMPS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Care Facilities

Oversold As of October 3, 2026

COMPASS Pathways Plc - American (CMPS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Care Facilities) last closed at $11.90. The rating moved from Strong Oversold to Oversold on October 3, 2026.

See all oversold Healthcare stocks →

AI analysis

COMPASS Pathways Plc - American (CMPS) is primarily a clinical-stage developer where valuation hinges on trial outcomes, regulatory clarity and financing. The company lacks commercial revenue, creating dependence on successful readouts, partnership or capital raises to preserve runway. Current risk-off market conditions and evolving payer/regulatory posture for novel CNS/psychedelic therapies increase near-term volatility and dilution risk, while positive clinical signals or strategic deals would be clear upside catalysts.

Key factors

  • Clinical development progress in psychedelic-assisted therapy programs is the primary value driver; upcoming trial readouts or regulatory interactions could be binary catalysts.
  • No meaningful commercial revenue; valuation depends on trial outcomes, partnerships and future reimbursement decisions.
  • Cash runway and financing prospects influence dilution risk; market risk-off conditions make equity raises more expensive.
  • Market sentiment toward early-stage mental-health therapeutics is cautious; defensive flows and lighter volumes increase volatility.
  • Potential for strategic partnerships or licensing agreements could accelerate commercialization and de‑risk balance sheet needs.
  • Regulatory posture and evolving guidance for novel CNS/psychedelic treatments will materially affect approval timelines and market access.

Risks

  • Clinical trial failure or ambiguous efficacy/safety readouts could sharply reduce valuation.
  • Regulatory delays or stricter requirements for psychedelic therapies increase time-to-market and costs.
  • Cash runway insufficiency leading to dilutive financings at unfavorable prices.
  • Pricing, reimbursement and payer skepticism for novel therapies could limit commercial upside, especially under Medicare/IRA pressures.
  • High headline-driven volatility and low liquidity can amplify losses for investors and make secondary raises challenging.
  • Competition from other novel CNS approaches or small molecules that are cheaper to manufacture and distribute.
  • Legal/policy risk around scheduling and clinic delivery models for psychedelic-assisted therapy.
  • Macroeconomic risk-off periods compress speculative biotech valuations and reduce appetite for speculative financings.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CMPS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.